EUVIMEDEUVIMED entdecken
Crossref

Polycaprolactone-Coated Olanzapine-Loaded Solid Lipid Nanoparticles (PCL@OLZ-SLNs): A Ligand-Free Strategy for Sustained Release and Enhanced Oral Bioavailability

Mohadeseh Madadi, Gita Bagheri

Nanomedicine Research Journal · 2026-03 · 11 (1) · 84-104

DOI: 10.22034/nmrj.2026.01.009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nanomedicine Research Journal, 2026-03. Verfasst von Mohadeseh Madadi und 1 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Olanzapine-loaded solid lipid nanoparticles coated with polycaprolactone (PCL@OLZ-SLNs) were created as a ligand-free method for long-term oral olanzapine (OLZ) distribution. A three-level Box-Behnken design was used to improve uncoated OLZ-SLNs, screening five solid lipids and three formulation factors (lipid-to-drug ratio 10–30, Tween 80 concentration 1–2% w/v, sonication period 60–120 s). Based on stearic acid (lipid-to-drug ratio 15:1, 1.5% Tween 80, 90 s sonication), the best uncoated formulation showed a particle size of 168.5 ± 4.1 nm, zeta potential –30.1 ± 1.2 mV, entrapment efficiency 92.4 ± 1.8%, drug loading 7.4 ± 0.3%, and PDI 0.151 ± 0.012.With just 61.3 ± 2.6% released in 24 hours and >88% over 7 days via a non-Fickian mechanism with little burst effect, coating with 3% w/v PCL significantly slowed drug release and increased particle size to 223.7 ± 18.4 nm. In comparison to uncoated SLNs, oral administration of PCL@OLZ-SLNs to Sprague-Dawley rats (10 mg/kg) significantly delayed Tmax from ~1 h to ~2 h, increased Cmax 3.15-fold, extended elimination half-life from ~4.5 h to ~6 h, and enhanced AUC₀₋∞ approximately 5-fold (from 12.45 ± 0.15 to 62.90 ± 0.24 µg·h/mL; p < 0.001).All things considered, this simple, scalable, ligand-free approach provides good biocompatibility and a workable path to oral olanzapine medication at longer intervals (e.g., once weekly), which may enhance patient adherence in the treatment of schizophrenia.

Schlagwörter

schizophreniaantipsychotic agentsnanoparticlesdrug releaselipid nanoparticles

Zitieren

APA

Madadi, M., & Bagheri, G. (2026). Polycaprolactone-Coated Olanzapine-Loaded Solid Lipid Nanoparticles (PCL@OLZ-SLNs): A Ligand-Free Strategy for Sustained Release and Enhanced Oral Bioavailability. Nanomedicine Research Journal, 11(1), 84-104. https://doi.org/10.22034/nmrj.2026.01.009

Vancouver

Madadi M, Bagheri G. Polycaprolactone-Coated Olanzapine-Loaded Solid Lipid Nanoparticles (PCL@OLZ-SLNs): A Ligand-Free Strategy for Sustained Release and Enhanced Oral Bioavailability. Nanomedicine Research Journal. 2026;11(1):84-104. doi:10.22034/nmrj.2026.01.009

BibTeX
@article{Madadi2026,
  author = {Madadi, Mohadeseh and Bagheri, Gita},
  title = {Polycaprolactone-Coated Olanzapine-Loaded Solid Lipid Nanoparticles (PCL@OLZ-SLNs): A Ligand-Free Strategy for Sustained Release and Enhanced Oral Bioavailability},
  journal = {Nanomedicine Research Journal},
  year = {2026},
  volume = {11},
  number = {1},
  pages = {84--104},
  doi = {10.22034/nmrj.2026.01.009}
}
Kostenlos starten →